LCNB Corp’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $315K | Buy |
5,190
+200
| +4% | +$11.7K | 0.11% | 150 |
|
|
2025
Q4 | $269K | Buy |
4,990
+240
| +5% | +$11.5K | 0.09% | 164 |
|
|
2025
Q3 | $214K | Sell |
4,750
-50
| -1% | -$2.33K | 0.08% | 175 |
|
|
2025
Q2 | $222K | Hold |
4,800
| – | – | 0.08% | 174 |
|
|
2025
Q1 | $293K | Hold |
4,800
| – | – | 0.11% | 153 |
|
|
2024
Q4 | $271K | Sell |
4,800
-11
| -0.2% | -$615 | 0.1% | 156 |
|
|
2024
Q3 | $249K | Buy |
+4,811
| New | +$226K | 0.09% | 168 |
|
|
2024
Q2 | – | Sell |
-5,211
| Closed | -$283K | – | 174 |
|
|
2024
Q1 | $283K | Sell |
5,211
-608
| -10% | -$31K | 0.1% | 158 |
|
|
2023
Q4 | $299K | Sell |
5,819
-89
| -2% | -$4.67K | 0.12% | 144 |
|
|
2023
Q3 | $343K | Sell |
5,908
-1,353
| -19% | -$82.9K | 0.15% | 123 |
|
|
2023
Q2 | $464K | Sell |
7,261
-1,301
| -15% | -$87.2K | 0.2% | 111 |
|
|
2023
Q1 | $593K | Hold |
8,562
| – | – | 0.27% | 97 |
|
|
2022
Q4 | $616K | Buy |
8,562
+100
| +1% | +$7.54K | 0.29% | 95 |
|
|
2022
Q3 | $602K | Sell |
8,462
-312
| -4% | -$22.6K | 0.33% | 83 |
|
|
2022
Q2 | $676K | Hold |
8,774
| – | – | 0.35% | 82 |
|
|
2022
Q1 | $641K | Hold |
8,774
| – | – | 0.3% | 86 |
|
|
2021
Q4 | $547K | Sell |
8,774
-37
| -0.4% | -$2.17K | 0.25% | 101 |
|
|
2021
Q3 | $521K | Sell |
8,811
-260
| -3% | -$17.1K | 0.26% | 101 |
|
|
2021
Q2 | $606K | Buy |
9,071
+100
| +1% | +$6.52K | 0.3% | 88 |
|
|
2021
Q1 | $566K | Sell |
8,971
-510
| -5% | -$31.7K | 0.31% | 88 |
|
|
2020
Q4 | $588K | Sell |
9,481
-20
| -0.2% | -$1.23K | 0.33% | 80 |
|
|
2020
Q3 | $573K | Sell |
9,501
-510
| -5% | -$30.7K | 0.37% | 76 |
|
|
2020
Q2 | $589K | Hold |
10,011
| – | – | 0.4% | 71 |
|
|
2020
Q1 | $558K | Buy |
10,011
+88
| +0.9% | +$5.38K | 0.44% | 68 |
|
|
2019
Q4 | $637K | Buy |
9,923
+1,657
| +20% | +$94.9K | 0.39% | 70 |
|
|
2019
Q3 | $419K | Buy |
8,266
+949
| +13% | +$44.6K | 0.27% | 92 |
|
|
2019
Q2 | $332K | Sell |
7,317
-1
| -0% | -$47 | 0.23% | 100 |
|
|
2019
Q1 | $349K | Sell |
7,318
-145
| -2% | -$7.22K | 0.25% | 95 |
|
|
2018
Q4 | $388K | Buy |
7,463
+275
| +4% | +$14.8K | 0.32% | 83 |
|
|
2018
Q3 | $446K | Sell |
7,188
-80
| -1% | -$4.75K | 0.32% | 87 |
|
|
2018
Q2 | $402K | Buy |
7,268
+2,843
| +64% | +$154K | 0.36% | 71 |
|
|
2018
Q1 | $280K | Buy |
4,425
+372
| +9% | +$23.9K | 0.25% | 94 |
|
|
2017
Q4 | $248K | Sell |
4,053
-514
| -11% | -$32.1K | 0.22% | 105 |
|
|
2017
Q3 | $292K | Buy |
4,567
+33
| +0.7% | +$1.93K | 0.27% | 89 |
|
|
2017
Q2 | $253K | Buy |
4,534
+26
| +0.6% | +$1.42K | 0.25% | 95 |
|
|
2017
Q1 | $245K | Hold |
4,508
| – | – | 0.23% | 96 |
|
|
2016
Q4 | $263K | Buy |
+4,508
| New | +$246K | 0.26% | 94 |
|
Other funds holding BMY
VCM
VPM
LCNB Corp's BMY Position: Q1 2026 in Review
LCNB Corp increased its Bristol-Myers Squibb (BMY) stake by 4% in Q1 2026, buying an estimated $11.7K and bringing the position to 5,190 shares worth $315K. The position accounts for 0.11% of the portfolio, ranked #150.
LCNB Corp first reported a position in BMY in Q4 2016 and has held it in 37 quarters since. The position peaked at $676K in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- LCNB Corp held 5,190 shares of Bristol-Myers Squibb worth $315K as of Q1 2026.
- LCNB Corp bought 200 Bristol-Myers Squibb shares in Q1 2026, an estimated $11.7K.
- Bristol-Myers Squibb made up 0.11% of LCNB Corp's portfolio in Q1 2026, its #150 holding.
- LCNB Corp first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 37 quarters since.
- LCNB Corp's Bristol-Myers Squibb position peaked at $676K in Q2 2022.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on LCNB Corp's 13F filing for Q1 2026, filed 11 May 2026.